Study of AZD1222 for the Prevention of COVID-19 in Japan
A Phase I/II Randomized, Double-blind, Placebo-controlled Multicentre Study in Participants Aged 18 Years or Older to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Fukuoka-shi, Japan, 810-0021
- Research Site
-
Hachioji-shi, Japan, 192-0046
- Research Site
-
Minato-ku, Japan, 108-0075
- Research Site
-
Sumida-ku, Japan, 130-0004
- Research Site
-
Toshima-ku, Japan, 171-0021
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants aged 18 to 55 years (Cohort A and C), aged 56 to 69 years (Subcohorts B1 and D1), or aged ≥ 70 years (Subcohorts B2 and D2)
Exclusion Criteria:
- Known past laboratory-confirmed SARS-CoV-2 infection
- Positive SARS-CoV-2 RT PCR test at screening
- Seropositivity to SARS-CoV-2 at screening.
- Significant infection or other illness, including fever > 37.8°C on the day prior to or day randomization
- History of Guillain-Barré syndrome
- Any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting ≤ 14 days)
- History of allergy to any component of the vaccine
- Any history of angioedema
- Any history of anaphylaxis
- Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and uterine cervical carcinoma in situ)
- History of serious psychiatric condition likely to affect participation in the study
- Bleeding disorder (eg, factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture
- Suspected or known current alcohol or drug dependency
- Any other significant disease, disorder or finding which may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study or impair interpretation of the study data
- Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Part I
Cohort C will include healthy participants aged 18 to 55 years.
Cohort D will include healthy elderly participants aged ≥ 56 years.
In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2).
At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.
|
For subjects in part 1 will have that route of Administration as Intramuscular, 5 × 1010 vp (nominal, ± 1.5 × 1010 vp) on V2
|
|
Placebo Comparator: Part II
Cohort C will include healthy participants aged 18 to 55 years.
Cohort D will include healthy elderly participants aged ≥ 56 years.
In Cohort D, the elderly population is further divided into 2 different age subgroups; aged 56 to 69 years (Subcohort D1) and aged ≥ 70 years (Subcohort D2).
At least 30% of participants in Cohort D will be secured for participants with age ≥ 70 years.
|
For subjects in placebo will have that route of Administration as Intramuscular 0.9% (w/v) saline on V2 and V6.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Seroresponse to the Spike (S) Antigen of AZD1222 as Measured by Meso Scale Discovery (MSD) Serology Assay
Time Frame: Baseline (Day 1) and Day 57
|
Seroresponse is a binary outcome where a success is when the fold rise in titers compared with baseline is >= 4. The fold rise in titers was calculated as the ratio of the post-vaccination titer level to the baseline titer level.
The percentage of participants with a post-vaccination seroresponse (>= 4-fold rise in titers from Day 1 baseline value to Day 57) to the S antigen of AZD1222 as measured by MSD serology assay is reported.
|
Baseline (Day 1) and Day 57
|
|
Number of Participants With Local Solicited Adverse Events (AE)
Time Frame: From Day 1 up to 7 days post each dose of study vaccination, approximately 14 days
|
Solicited AEs are local or systemic predefined AEs for reactogenicity assessment.
Participants were given an axillary thermometer, tape measure, and access to app for the solicited AE eDiary, with instructions on use, along with the emergency 24-hour telephone number to contact the on-call study physician if needed.
Participants were instructed to record for 7 days following administration of each dose of AZD1222, the timing and severity of local and systemic solicited AEs, if applicable, and whether medication was taken to relieve the symptoms.
|
From Day 1 up to 7 days post each dose of study vaccination, approximately 14 days
|
|
Number of Participants With Systemic Solicited AEs
Time Frame: From Day 1 up to 7 days post each dose of study vaccination, approximately 14 days
|
Solicited AEs are local or systemic predefined AEs for reactogenicity assessment.
Participants were given an axillary thermometer, tape measure, and access to app for the solicited AE eDiary, with instructions on use, along with the emergency 24-hour telephone number to contact the on-call study physician if needed.
Participants were instructed to record for 7 days following administration of each dose of AZD1222, the timing and severity of local and systemic solicited AEs, if applicable, and whether medication was taken to relieve the symptoms.
|
From Day 1 up to 7 days post each dose of study vaccination, approximately 14 days
|
|
Number of Participants With AEs, Serious AEs (SAE) and Adverse Event of Special Interest (AESI) Occurring Post Each Dose of Study Vaccination
Time Frame: From Day 1 up to 28 days post each dose of study vaccination, approximately 57 days
|
An AE is the development of any untoward medical occurrence in a clinical study participant administered medicinal product and which does not necessarily have a causal relationship with this medicinal product.
An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An SAE is an AE occurring during any study phase that fulfils one or more of the following criteria: death; immediately life-threatening; in-participant hospitalization or prolongation of existing hospitalization; persistent or significant disability or incapacity; congenital abnormality or birth defect; an important medical event.
The AESIs were events of scientific and medical interest specific to the further understanding of the study vaccination safety profile and required close monitoring and rapid communication by the investigators to the sponsor.
|
From Day 1 up to 28 days post each dose of study vaccination, approximately 57 days
|
|
Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters
Time Frame: From Day 1 up to 28 days post each dose of study vaccination, approximately 57 days
|
Clinical laboratory values were evaluated for each laboratory parameter as applicable including hematology and clinical chemistry.
The baseline was defined as the last non-missing measurement taken prior to the first dose of study vaccination (including unscheduled measurements, if any).
|
From Day 1 up to 28 days post each dose of study vaccination, approximately 57 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Seroresponse to the Receptor-Binding Domain (RBD) Antigen of AZD1222 as Measured by MSD Serology Assay
Time Frame: Baseline (Day 1) and Day 57
|
Seroresponse is a binary outcome where a success is when the fold rise in titers compared with baseline is >= 4. The fold rise in titers was calculated as the ratio of the post-vaccination titer level to the baseline titer level.
The percentage of participants with a post-vaccination seroresponse (>= 4-fold rise in titers from Day 1 baseline value to Day 57) to the RBD antigen of AZD1222 as measured by MSD serology assay is reported.
|
Baseline (Day 1) and Day 57
|
|
Geometric Mean Titers (GMTs) for SARS-CoV-2 S and RBD Antibodies as Measured by MSD Serology Assay
Time Frame: Baseline (Day 1) and Days 15, 29, 43, 57, 183, and 365
|
The GMT was calculated as the antilogarithm of Σ(log base 2 transformed titer/n), i.e. as the anti-logarithm transformation of the mean of the log-transformed titer, where 'n' is the number of participants with titer information.
|
Baseline (Day 1) and Days 15, 29, 43, 57, 183, and 365
|
|
Geometric Mean Fold Rise (GMFR) for SARS-CoV-2 S and RBD Antibodies as Measured by MSD Serology Assay
Time Frame: Baseline (Day 1) and Days 15, 29, 43, 57, 183, and 365
|
The fold rise was calculated as the ratio of the post-vaccination titer level to the baseline titer level, where baseline was defined as the last measurement taken before the first dose of study vaccination.
The GMFR was calculated as anti-logarithm of Σ (log base 2 transformed (post-vaccination titer/ pre-vaccination titer)/n).
Where 'n' is the number of participants with titer information.
|
Baseline (Day 1) and Days 15, 29, 43, 57, 183, and 365
|
|
Percentage of Participants With Seroresponse to SARS-CoV-2 Neutralizing Antibodies (nAb) of AZD1222 as Measured by Pseudo-Neutralization Assay
Time Frame: Baseline (Day 1) and Day 57
|
Seroresponse is a binary outcome where a success is when the fold rise in titers compared with baseline is >= 4. The fold rise in titers was calculated as the ratio of the post-vaccination titer level to the baseline titer level.
The percentage of participants with a post-vaccination seroresponse (>= 4-fold rise in titers from Day 1 baseline value to Day 57) to SARS-CoV-2 nAb of AZD1222 as measured by pseudo-neutralization assay is reported.
|
Baseline (Day 1) and Day 57
|
|
GMTs for SARS-CoV-2 nAb as Measured by Pseudo-Neutralization Assay
Time Frame: Baseline (Day 1) and Days 29, 57, 183, and 365
|
The GMT was calculated as the antilogarithm of Σ(log base 2 transformed titer/n), i.e. as the anti-logarithm transformation of the mean of the log-transformed titer, where 'n' is the number of participants with titer information.
|
Baseline (Day 1) and Days 29, 57, 183, and 365
|
|
GMFR for SARS-CoV-2 nAb as Measured by Pseudo-Neutralization Assay
Time Frame: Baseline (Day 1) and Days 29, 57, 183, and 365
|
The fold rise was calculated as the ratio of the post-vaccination titer level to the baseline titer level, where baseline was defined as the last measurement taken before the first dose of study vaccination.
The GMFR was calculated as anti-logarithm of Σ (log base 2 transformed (post-vaccination titer/ pre-vaccination titer)/n).
Where 'n' is the number of participants with titer information.
|
Baseline (Day 1) and Days 29, 57, 183, and 365
|
|
Number of Participants With SAEs and AESIs Occurring Throughout the Study
Time Frame: From Day 1 up to final DCO of 17 January 2022, up to a maximum of 365 days
|
An SAE is an AE occurring during any study phase that fulfils one or more of the following criteria: death; immediately life-threatening; in-participant hospitalization or prolongation of existing hospitalization; persistent or significant disability or incapacity; congenital abnormality or birth defect; an important medical event.
The AESIs were events of scientific and medical interest specific to the further understanding of the study vaccination safety profile and required close monitoring and rapid communication by the investigators to the sponsor.
|
From Day 1 up to final DCO of 17 January 2022, up to a maximum of 365 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D8111C00002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.